Pharmaceuticals: Commission refines intellectual property rules

Pharmaceuticals 2018 European Commission

The EPO – European Patent Office, has announced the 15 inventors short-listed for this prestigious prize – pioneers in a range of technical fields, from green plastics and oil-spill clean-up, to pharmaceuticals, medical imaging and satellite navigation. Gert-Jan Gruter (The Netherlands), nominated for the European Inventor Award 2017 in the category “Small and medium-sized enterprises – SMEs”. © European Patent Organisation , 2017 / Source: EC – Audiovisual Service / Photo: Heinz Troll

This article is brought to you in association with the European Commission.

The Commission is proposing a targeted adjustment to intellectual property rules to help Europe’s pharmaceutical companies tap into fast-growing global markets and foster jobs, growth and investments in the EU.

The EU has a strong intellectual property rights framework in place which protects Europe’s know-how and sustains the pharmaceutical industry’s world-class innovation capacity. To improve the current system further and remove a major competitive disadvantage of EU manufacturers, the Commission proposes a targeted amendment: the so-called ‘export manufacturing waiver’ to Supplementary Protection Certificates.

Supplementary Protection Certificates (SPCs) extend patent protection for medicinal products which must undergo lengthy testing and clinical trials prior to obtaining regulatory marketing approval. Thanks to the waiver, in the future EU-based companies will be entitled to manufacture a generic or biosimilar version of an SPC-protected medicine during the term of the certificate, if done exclusively for the purpose of exporting to a non-EU market where protection has expired or never existed. The waiver will support Europe’s pioneering role in pharmaceutical research and development.

Vice-President Jyrki Katainen, responsible for Jobs, Growth Investment and Competitiveness, said: “Europe is and should remain at the forefront of pharmaceutical research and manufacturing. Our rules on intellectual property protection of pharmaceuticals promote innovation and creativity. We are committed to the core rights and the length of this protection, which remain unchanged. Today we are proposing a well-calibrated adjustment to the current regime to remove a legal barrier that was preventing our companies from competing on equal terms on global markets where competition is fierce. We want to make sure that our pharmaceutical industry reaps the benefits of such competition.”

Elżbieta Bieńkowska, Commissioner for Internal Market, Industry, Entrepreneurship and SMEs, added: “Today’s proposal strikes a balance between the imperative to ensure the attractiveness of Europe for innovative pharmaceutical companies and the urgency to allow EU based generics and biosimilar to compete on the global markets. This will help create growth and high-skilled jobs in the EU. It could generate €1 billion net additional sales per year and up to 25 000 new jobs over 10 years. It will particularly benefit the many small and medium-sized enterprises in the field. In the medium term, more competition will improve patients’ access to a wider choice of medicines and alleviate public budgets.”

With the waiver, intellectual property (IP) protection for medicine production in Europe will remain the strongest in the world. SPC-protected medicines will retain their full market exclusivity in the EU.

The proposal is accompanied by a series of safeguards which will create transparency and prevent IP-infringing products from entering Member State markets. It goes hand in hand with other EU initiatives to defend Europe’s know-how and innovation leadership and protect patients against counterfeited medicines. It also complements the EU’s overall approach to ensure free and fair trade, characterised by open markets, for EU-based manufacturers.

Today’s proposal amends Regulation 469/2009 on the supplementary protection certificate for medicinal products. Once adopted by the European Parliament and Council, it will be directly applicable in all EU Member States.

Background

EU and global pharmaceutical markets are undergoing profound changes. Global demand for medicines has increased massively, reaching over €1 trillion in 2017. Alongside this, there is a shift towards an ever-greater market share for generics and biosimilars. Traditionally the EU has played a pioneering role in pharmaceutical research and development, including generic medicines and biosimilars. But this leadership position is under threat.

Supplementary protection certificates (SPCs) are an intellectual property right first introduced in the EU in 1992 as an extension to a patent right. Pharmaceutical SPCs aim to offset the loss of effective patent protection for medicines that occurs due to the compulsory lengthy testing and clinical trials these products require prior to obtaining regulatory marketing approval. An SPC can extend a patent right for a maximum of five years.

EU SPC rules are the strongest in the world. While they aim to reward investment in innovation and protect intellectual property, SPCs can put EU based manufacturers of generics and biosimilar at a disadvantage with non-EU based industry, thereby preventing further innovation and job creation in Europe. Indeed, during the SPC period of protection of the product in the EU, EU-based manufacturers of generic and/or biosimilar-related products cannot currently manufacture for any purpose, including export outside the EUto countries where SPC protection has expired or does not exist, while manufacturers based in those non-EU countries can do so. This major competitive disadvantage entails a risk of delocalisation of manufacturing and loss of investment in Europe. The certificate also makes it more difficult for EU manufacturers to enter the EU market immediately after its expiry, given that they are not in a position to build up production capacity until the protection provided by the certificate has lapsed.

Many SPC protections will start to lapse from 2020, as a significant number of medicinal products will enter the public domain, since their patent or SPC terms will expire. This development will generate significant new market opportunities for generics, and for biosimilars in particular. There is an urgent need to adjust the existing regulation to this situation, as the markets for generics and biosimilars are highly competitive and steadily growing and the investment decisions on the localisation of the production are being made well in advance.

Today’s proposal was announced in the Commission’s 2015 Single Market Strategy, and follows various studies, an extensive consultation and a European Parliament resolution endorsing the need to introduce before 2019 an SPC manufacturing waiver.

Advertising

Advertising

Advertising

Advertising

Advertising

Advertising

the sting Milestone

Featured Stings

Can we feed everyone without unleashing disaster? Read on

These campaigners want to give a quarter of the UK back to nature

How to build a more resilient and inclusive global system

Stopping antimicrobial resistance would cost just USD 2 per person a year

MWC 2016: IoT experts fret over fragmentation

What paleoecology can teach us about fires in the Amazon

3 ways to fight short-termism and relaunch Europe

EU Parliament semi worried over democratic deficit

These are the countries where most adults still don’t have a smartphone

Scoring for the environment: what Mathieu Flamini’s top-flight football career taught him about leadership

We can decide to live within the limits of our planet

Eurozone economy desperately needs internally driven growth

Guterres calls for ‘maximum restraint’ following drone assault on key Saudi oil facility

New Zealand will have a new ‘well-being budget,’ says Jacinda Ardern

The business case for investing in sustainable plastics

Deaths from far-right terrorism have more than tripled in the West

Why is Grexit again in the news? Who is to pay for Eurozone’s banking problems?

Merkel had it her way with the refugees & immigrants but can Greece and Turkey deliver?

Turkey presents a new strategy for EU accession but foreign policy could be the lucky card

The latest emoji are more inclusive – but who approves them?

Thursday’s Daily Brief: Climate emergency, call to support breastfeeding, rising political heat and new investigation board for Syria

German banks suffer of nausea amidst rough seas

The strong version of the EU banking union gains momentum

‘No steps taken’ so far to end Israel’s illegal settlement activity on Palestinian land – UN envoy

GSMA Announces New Keynote Speakers, Event Updates for 2019 “MWC Los Angeles, in Partnership with CTIA”

Study: Trade supports over 36 million jobs across the EU

UN Security Council welcomes results of Mali’s presidential elections

Companies can help solve water scarcity. Here’s how

‘Virtual Biopsy’ device detects skin tumours in 15 minutes

UN chief condemns suspected Boko Haram attacks targeting Eid al-Fitr celebrations in Nigeria

UN agencies call for more resettlement and end to detention of asylum seekers in Libya

How distorted is the EU labour market by this crisis?

Monday’s Daily Brief: human rights in the Near East and a Forum for Refugees

EU finally agreed to cut roaming charges in 2017 but criticism is always there

Millions of young lives at risk due to humanitarian funding shortfall: UNICEF

This is why mountains matter more than you think

Further reforms in Japan needed to meet the challenges of population ageing and high public debt

These are the countries that eat the most meat

Advocate General ‘outlaws’ Data Retention Directive

Central African Republic: Guterres says UN mission committed to protecting civilians, helping stabilize country, as violence flares

EU Commission: Growth first then fiscal consolidation

5 ways blockchain can transform the world of impact investing

The Eurogroup offered a cold reception to IMF’s director for Europe

A Sting Exclusive: EU Commission’s Vice President Šefčovič accentuates the importance of innovation to EU’s Energy Union

WEF Davos 2016 LIVE: “European unity and cooperation is being called on question”, Vice President Joe Biden criticizes from Davos

Will the EU reconsider Frontex’s role in light of accusations about violations of migrants’ human rights?

UN condemns attack on Ebola treatment centre in DR Congo which left doctor dead, two others injured

‘No-deal’ Brexit preparedness: European Commission takes stock of preparations and provides practical guidance to ensure coordinated EU approach

The US bugged Europe: Is this news?

World Television Day celebrates an integral part of modern life

Chart of the day: This is what violence does to a nation’s GDP

Here are 3 ways venture capital can fund a better future

There are now four competing visions of the internet. How should they be governed?

The world needs a grand coalition to tackle climate change

Who cares about the unity of Ukraine?

Civilians ‘must never be a target,’ says UN in Afghanistan, amid troubling number of casualties during Ramadan

What UK and EU risk if Brexit “wins” these elections

French full-body veil ban, violated women’s freedom of religion: UN Human Rights Committee

OECD and European Commission join forces to further support structural reforms in European countries

Much more than a ‘lifeline’ for millions of households, remittances can spur global growth, says UN agency

Libya detention centre airstrike could amount to a war crime says UN, as Guterres calls for independent investigation

The Sichuan Province of China presents its cultural treasure to the EU

Terrorist content online should be removed within one hour, says EP

Wednesday’s Daily Brief: Syrian detainees, Zimbabwe hunger crisis, Kabul attack, Mexico disappearances, new tech to feed the world

More Stings?

Speak your Mind Here

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s